Deferral of Coronary Revascularization in Patients With Reduced Ejection Fraction Based on Physiological Assessment: Impact on Long-Term Survival.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
04 10 2022
Historique:
pubmed: 22 9 2022
medline: 6 10 2022
entrez: 21 9 2022
Statut: ppublish

Résumé

Background Deferring revascularization in patients with nonsignificant stenoses based on fractional flow reserve (FFR) is associated with favorable clinical outcomes up to 15 years. Whether this holds true in patients with reduced left ventricular ejection fraction is unclear. We aimed to investigate whether FFR provides adjunctive clinical benefit compared with coronary angiography in deferring revascularization of patients with intermediate coronary stenoses and reduced left ventricular ejection fraction. Methods and Results Consecutive patients with reduced left ventricular ejection fraction (≤50%) undergoing coronary angiography between 2002 and 2010 were screened. We included patients with at least 1 intermediate coronary stenosis (diameter stenosis ≥40%) in whom revascularization was deferred based either on angiography plus FFR (FFR guided) or angiography alone (angiography guided). The primary end point was the cumulative incidence of all-cause death at 10 years. The secondary end point (incidence of major adverse cardiovascular and cerebrovascular events) was a composite of all-cause death, myocardial infarction, any revascularization, and stroke. A total of 840 patients were included (206 in the FFR-guided group and 634 in the angiography-guided group). Median follow-up was 7 years (interquartile range, 3.22-11.08 years). After 1:1 propensity-score matching, baseline characteristics between the 2 groups were similar. All-cause death was significantly lower in the FFR-guided group compared with the angiography-guided group (94 [45.6%] versus 119 [57.8%]; hazard ratio [HR], 0.65 [95% CI, 0.49-0.85];

Identifiants

pubmed: 36129045
doi: 10.1161/JAHA.122.026656
pmc: PMC9673723
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e026656

Références

Circulation. 2018 Apr 3;137(14):1475-1485
pubmed: 29162610
J Am Heart Assoc. 2020 Dec 15;9(24):e017729
pubmed: 33283600
Am Heart J. 2006 Jul;152(1):102-9
pubmed: 16824838
J Am Coll Cardiol. 1999 Dec;34(7):1939-46
pubmed: 10588207
Eur Heart J. 2014 Oct 21;35(40):2831-8
pubmed: 24644308
Eur Heart J. 2015 Dec 1;36(45):3182-8
pubmed: 26400825
Eur Heart J. 2020 May 1;41(17):1665-1672
pubmed: 31419282
J Am Coll Cardiol. 2021 May 18;77(19):2432-2447
pubmed: 33985688
Circ Cardiovasc Imaging. 2017 Jul;10(7):
pubmed: 28687539
J Am Heart Assoc. 2020 Feb 4;9(3):e015502
pubmed: 32013699
Circulation. 2018 Feb 27;137(9):961-972
pubmed: 29483172
N Engl J Med. 2012 Sep 13;367(11):991-1001
pubmed: 22924638
J Am Coll Cardiol. 2002 Jan 16;39(2):210-8
pubmed: 11788209
JACC Cardiovasc Interv. 2016 Mar 14;9(5):453-9
pubmed: 26896888
N Engl J Med. 2009 Jun 11;360(24):2503-15
pubmed: 19502645
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
N Engl J Med. 2011 Apr 28;364(17):1607-16
pubmed: 21463150
J Am Coll Cardiol. 2019 Sep 10;74(10):1420-1421
pubmed: 31488278
N Engl J Med. 1997 Jan 23;336(4):251-7
pubmed: 8995087
N Engl J Med. 2019 Aug 22;381(8):739-748
pubmed: 31433921
Circulation. 2020 Nov 3;142(18):1725-1735
pubmed: 32862662
J Am Coll Cardiol. 2016 Aug 16;68(7):742-53
pubmed: 27515335
N Engl J Med. 2016 Apr 21;374(16):1511-20
pubmed: 27040723
Circ Heart Fail. 2017 Jan;10(1):
pubmed: 28087687
N Engl J Med. 2020 Apr 9;382(15):1395-1407
pubmed: 32227755
N Engl J Med. 2009 Jan 15;360(3):213-24
pubmed: 19144937
Circulation. 2012 Oct 23;126(17):2115-24
pubmed: 23008442
JACC Heart Fail. 2018 Jun;6(6):517-526
pubmed: 29852933
J Am Coll Cardiol. 2007 Feb 27;49(8):839-48
pubmed: 17320741
Int J Cardiol. 2016 Feb 1;204:206-10
pubmed: 26670174

Auteurs

Emanuele Gallinoro (E)

Cardiovascular Center Aalst Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium.
Department of Translational Medical Sciences University of Campania "Luigi Vanvitelli" Naples Italy.

Pasquale Paolisso (P)

Cardiovascular Center Aalst Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium.
Department of Advanced Biomedical Sciences University of Naples Federico II Naples Italy.

Giuseppe Di Gioia (G)

Cardiovascular Center Aalst Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium.

Kostantinos Bermpeis (K)

Cardiovascular Center Aalst Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium.

Estefania Fernandez-Peregrina (E)

Cardiovascular Center Aalst Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium.

Alessandro Candreva (A)

Cardiovascular Center Aalst Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium.
Department of Cardiology Zurich University Hospital Zurich Switzerland.
PoliToBIO Med Lab Department of Mechanical and Aerospace Engineering Politecnico di Torino Italy.

Giuseppe Esposito (G)

Cardiovascular Center Aalst Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium.
Department of Advanced Biomedical Sciences University of Naples Federico II Naples Italy.

Davide Fabbricatore (D)

Cardiovascular Center Aalst Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium.
Department of Advanced Biomedical Sciences University of Naples Federico II Naples Italy.

Dario Tino Bertolone (DT)

Cardiovascular Center Aalst Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium.
Department of Advanced Biomedical Sciences University of Naples Federico II Naples Italy.

Jozef Bartunek (J)

Cardiovascular Center Aalst Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium.

Marc Vanderheyden (M)

Cardiovascular Center Aalst Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium.

Eric Wyffels (E)

Cardiovascular Center Aalst Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium.

Jeroen Sonck (J)

Cardiovascular Center Aalst Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium.

Carlos Collet (C)

Cardiovascular Center Aalst Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium.

Bernard De Bruyne (B)

Cardiovascular Center Aalst Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium.
Department of Cardiology Lausanne University Hospital Lausanne Switzerland.

Emanuele Barbato (E)

Cardiovascular Center Aalst Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium.
Department of Advanced Biomedical Sciences University of Naples Federico II Naples Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH